Jaume Alijotas Reig Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca Email Jaume Alijotas Reig Email Institutions of which they are part Head of group Systemic Diseases Vall Hebron Institut de Recerca
Research lines Endothelial senescence and their pleiotropic effects onto inflamatory processes, inmunological response and angiogenesis. Identification at the molecular level of pathways and proteins associated with the senescence of endothelial cells linked to aging and inflamatory responses. New candidate targets for therapeutic intervention at the clinical level and as new molecular moieties for nanomedicine approaches to improve aging related pathologies caused by endothelial inflamatory based senescence. IP: Jaume Alijotas Reig Immunologic lesional mechanisms in late adverse reactions against bioimplants. The late clinical manifestations that arise when bioimplants are applied seem to have an immunologic basis. We are studying both the histological characteristics and the lesional mechanisms of the most frequently used implants. We try to analyze the role that bacteria may have in the induction and/or maintenance of these reactions and the possible correlation between particular HLA haplotypes and the adverse effects. IP: Jaume Alijotas Reig Predictive kit to detect the possible establishment of late adverse effects related to bioimplants used in clinical practice. A high variability in the prevalence of adverse effects with an immunologic basis seems to be related with any implant used in clinical practice. We have managed to find a particular association of HLA haplotypes that increase the risk for developing these effects up to 600 times. We are nowadays working on setting up a safe and reliable biochip or kit which predicts this risk easily in a routine test. IP: Jaume Alijotas Reig Immunobiology and immunopathology of recurrent pregnancy loses and spontaneous loses. Around 2-3% of reproductive-age couples suffer recurrent pregnancy loses. Almost 18% of couples that wish to have children suffer infertility problems. Simultaneously, 2-3% of all pregnant women are diagnosed with spontaneous loses. The expression of HLA molecules, specially type G, the degree of trophoblastic apoptosis, the outsourcing of new neoantigens such as phospholipids, the balance between Th1/Th2/Th3 cytokines, the type and quantity of CD4+CD25+Foxp3+ lymphocytes, the kind and the activity of uterine NK cells (uNK) cells, the presence or absence of blocking antibodies, and other mechanisms play different roles in the achievement of the so-called "tolerant microenvironment" needed to develop a normal pregnancy. Therefore, both autoimmune and alloimmune mechanisms are important. We aim at studying which isolated, and specially associated, anomalies can be identified as risk markers to be able to evaluate possible treatments. IP: Jaume Alijotas Reig Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Next page › Last page » Projects Factores angiogénicos durante la gestación y riesgo cardiovascular a medio-largo plazo en las pacientes con preeclampsia. Abordaje clínico y experimental. IP: Jaume Alijotas Reig Collaborators: Manel Mendoza Cobaleda, Josep Perapoch López Funding agency: Instituto de Salud Carlos III Funding: 71995 Reference: PI16/01997 Duration: 01/01/2017 - 31/12/2019 Incorporación del ratio sFlt1/PlGF en el diagnóstico y clasificación de preeclampsia: Ensayo clínico randomizado (EuroPE estudio) IP: Elisa Llurba Olivé Collaborators: Jaume Alijotas Reig, Manel Mendoza Cobaleda Funding agency: Instituto de Salud Carlos III Funding: 111925 Reference: PI16/00375 Duration: 01/01/2017 - 13/06/2017 Sulfato de magnesio en pauta continua versus discontinua en la conducta expectante de la preeclampsia grave: ensayo clínico aleatorizado IP: Anna Suy Franch Collaborators: Jaume Alijotas Reig Funding agency: Ministerio Sanidad Funding: 57120 Reference: EC11-474 Duration: 01/01/2012 - 31/12/2018 Sulfato de magnesio en pauta continua versus discontinua en la conducta expectante de la preeclampsia grave: ensayo clínico randomizado IP: Anna Suy Franch Collaborators: Jaume Alijotas Reig, Maria del Mar Goya Canino Funding agency: Instituto de Salud Carlos III Funding: 62012.5 Reference: PI11/00388 Duration: 01/01/2012 - 30/06/2016 Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Next page › Last page »
